Glutathione is often called the body's master antioxidant, and N-acetylcysteine (NAC) is one of the most studied ways to support it. Below is what the research shows, where it stops, and how the physician-guided Calibrate IV NAC Injection HomeKit fits into a wellness plan. Skip the waiting room, but never skip the evidence.

What is NAC, and how does it support glutathione?

NAC is the acetylated form of L-cysteine, an amino acid. Cysteine is the limiting building block your cells use to make glutathione, a small antioxidant molecule built from glutamate, cysteine and glycine. By supplying cysteine, NAC supports the body's own glutathione production.

A pharmacology review (Rushworth & Megson, Pharmacology & Therapeutics, 2014) makes a useful point: NAC's antioxidant benefit appears to depend largely on conversion to intracellular glutathione, rather than on NAC acting as a stand-alone scavenger. That is why we describe NAC as antioxidant support through glutathione, not as a stand-alone antioxidant shield.

On the human side, a small randomized, double-blind, placebo-controlled trial in older adults (Sekhar et al., Baylor College of Medicine, 2019, reported as a conference abstract) gave 16 weeks of GlyNAC, a combination of glycine and NAC. Participants had lower markers of oxidative stress and inflammation. Two caveats: it was a combination product, not NAC alone, and it used oral doses far higher than a HomeKit dose.

Why an injectable?

Oral NAC is poorly absorbed. In six healthy volunteers, oral bioavailability was about 4% for reduced NAC and about 9% for total NAC (Olsson et al., European Journal of Clinical Pharmacology, 1988), largely because the gut and liver break it down before it reaches circulation. A review in Kidney International Reports (2024) puts oral bioavailability at roughly 10%. Injection bypasses that first-pass step.

That rationale is sound, but it is worth being precise: the human pharmacokinetic studies we found compare oral with intravenous dosing (for example, Medved et al., European Journal of Clinical Pharmacology, 2005, in healthy men). We did not find published human studies of subcutaneous or intramuscular NAC at the dose used in the HomeKit.

What the research shows, by area

Liver and detox pathways

Intravenous NAC is the long-established hospital antidote for acetaminophen overdose. In a randomized, double-blind, placebo-controlled trial from the Acute Liver Failure Study Group (Lee et al., Gastroenterology, 2009), IV NAC improved transplant-free survival in patients with early-stage acute liver failure not caused by acetaminophen.

These were critically ill patients receiving a weight-based IV loading dose followed by a 72-hour infusion, many grams in total for an adult. The findings do not show that a 100 mg injection supports liver function in healthy adults. What they do show is that NAC's glutathione-related biology is clinically meaningful in the right setting. Glutathione is central to how the liver processes compounds the body needs to clear, which is the basis for our "supports the body's natural detoxification pathways" language, and nothing more.

Respiratory health

NAC is a mucolytic, meaning it helps thin mucus. Cochrane systematic reviews of oral mucolytics (Poole et al.), summarized by NIHR Evidence, found fewer flare-ups in people with chronic bronchitis or COPD, with benefits likely to be small and smaller in more recent COPD trials. A network meta-analysis (Cazzola et al., COPD, 2018) found that only NAC at 1,200 mg/day significantly reduced exacerbations versus placebo, while 600 mg/day did not.

These trials were in people with chronic lung conditions taking oral NAC at daily doses well above the HomeKit's 100 mg per injection.

Mood and focus

The evidence here is promising but mixed, and almost entirely in clinical populations. A meta-analysis of five randomized trials (574 participants with psychiatric conditions) found a modest reduction in depressive symptoms (Fernandes et al., Journal of Clinical Psychiatry, 2016). A separate meta-analysis of adjunctive NAC (Zheng et al., Acta Psychiatrica Scandinavica, 2018) found a benefit in schizophrenia but not in bipolar disorder, with only a small effect on depression in the single major depressive disorder trial.

For cognition, a systematic review of 12 studies (Skvarc et al., Neuroscience & Biobehavioral Reviews, 2017) found some signals of improvement but concluded that small, varied studies made firm conclusions impossible. Only three of the studies involved healthy participants. In short, NAC is an active area of research, and we do not claim it boosts energy or sharpens focus.

How the Calibrate IV NAC HomeKit works

The HomeKit is designed for physician-guided use at home. After you complete a brief medical history questionnaire, a licensed provider reviews your information and confirms whether treatment is appropriate for you. If approved, your kit ships directly to your door, and a physician reaches out within 24 hours of purchase for safety screening, dosing guidance, and any questions.

Each kit includes NAC injections (1 mL, or 100 mg, per dose) in your choice of subcutaneous or intramuscular administration, syringes, alcohol pads, and an online telehealth consultation. The recommended frequency is twice per week, and a 30-day or 6-month supply is available.

Who should talk to a physician first?

Everyone, which is why screening is built in. If you are pregnant or nursing, manage a chronic condition, or take prescription medication, discuss NAC with your physician before starting. Our team can walk you through the process at 1-844-416-2546 or concierge@calibrateiv.com.

Frequently asked questions

Is NAC the same as glutathione?

No. NAC is a precursor that supplies cysteine, which the body uses to make glutathione. Glutathione itself is poorly absorbed when taken by mouth: in seven healthy volunteers, a 3 g oral dose did not significantly raise plasma glutathione (Witschi et al., European Journal of Clinical Pharmacology, 1992), which is one reason precursor strategies are studied.

Will NAC treat or cure a condition?

No. The HomeKit is a wellness offering intended to support, not to diagnose, treat, cure or prevent any disease.

Where can I learn more?

Visit our NAC HomeKit page or browse the Calibrate IV education hub.

Ready to see if NAC fits your wellness plan? Start with a physician-guided consultation.

References

1. Rushworth GF, Megson IL. Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits. Pharmacol Ther. 2014;141(2):150-159. PubMed (narrative review)
2. Sekhar RV, Kumar P, Hsu JW, et al. Correcting glutathione deficiency and mitochondrial dysfunction in older humans: a randomized clinical trial. Innov Aging. 2019 (conference abstract). PMC (human RCT, small, GlyNAC combination)
3. Olsson B, Johansson M, Gabrielsson J, Bolme P. Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine. Eur J Clin Pharmacol. 1988. Springer (human pharmacokinetic study, n=6)
4. N-acetylcysteine in kidney disease: molecular mechanisms, pharmacokinetics, and clinical effectiveness. Kidney Int Rep. 2024. PMC (review)
5. Medved I, Brown M, Bjorksten A, McKenna M. Pharmacokinetics of intravenous N-acetylcysteine in men at rest and during exercise. Eur J Clin Pharmacol. 2005;60(10):717-723. PMID 15619135 (human pharmacokinetic study, IV)
6. Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology. 2009;137(3):856-864. PMC (human RCT, IV, critically ill patients)
7. Poole P, et al. Mucolytic agents versus placebo for chronic bronchitis or COPD. Cochrane Database Syst Rev. Summarized by NIHR Evidence (systematic review, oral mucolytics)
8. Cazzola M, Rogliani P, Calzetta L, Hanania NA, Matera MG. Impact of mucolytic agents on COPD exacerbations: a pair-wise and network meta-analysis. COPD. 2018;14(5):552-563. (network meta-analysis)
9. Fernandes BS, et al. N-acetylcysteine in depressive symptoms and functionality: a systematic review and meta-analysis. J Clin Psychiatry. 2016;77(4):e457-e466. PubMed (meta-analysis of RCTs, psychiatric populations)
10. Zheng W, Zhang QE, Cai DB, et al. N-acetylcysteine for major mental disorders: a systematic review and meta-analysis of randomized controlled trials. Acta Psychiatr Scand. 2018;137(5):391-400. PubMed (meta-analysis of RCTs)
11. Skvarc DR, Dean OM, Byrne LK, et al. The effect of N-acetylcysteine (NAC) on human cognition: a systematic review. Neurosci Biobehav Rev. 2017;78:44-56. PubMed (systematic review)
12. Witschi A, Reddy S, Stofer B, Lauterburg BH. The systemic availability of oral glutathione. Eur J Clin Pharmacol. 1992;43(6):667-669. PubMed (human study, n=7)

This article is for educational purposes only and is not medical advice. The statements here are not intended to diagnose, treat, cure or prevent any disease. Individual results vary. Talk with your physician before starting any new wellness protocol.